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Abstract
In cancer cells, the oncogenic mutant p53 (mtp53) protein is present at high levels and gain-of-function (GOF) activities with
more expression of mtp53 proteins contribute to tumor growth and metastasis. Robust analytical approaches that probe
the degree of metastasis of cancer cells in connection with the mtp53 activity will be extremely useful not only for
establishing a better cancer prognosis but also understanding the fundamental mechanism of mtp53 oncogenic action.
Here we assessed the influence of mtp53 in breast cancers to the mechanical property of breast cancer cells. Recently,
ovarian and kidney cancer cell lines have been shown to have higher cellular elasticity as compared to normal cells assessed
by monitoring the degree of deformation under hyposmotic pressure. To make fast detection in large scale, the impedance
measurement was applied to monitor the swelling ratio of cells with time. The results showed that knockdown of mtp53
leads to decrease in cell swelling. In addition, by means of two types of impedimetric detection systems we consistently
detected enhancement of impedance signal in mtp53-expressing breast cancer cells. Based on this observation we
hypothesize that highly expressed mtp53 in metastatic mutant breast cancers can promote tumor progression by making
cells more deformable and easier to spread out through extracellular matrix. The identification via the electric measurement
can be accomplished within 10 minutes. All results in this report suggest that electric probing for the extent of the mtp53
expression of breast cancer cells may serve as a meaningful fingerprint for the cancer diagnostics, and this outcome will also
have an important clinical implication for the development of mtp53-based targeting for tumor detection and treatment.
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Introduction
Constant efforts are being made to improve diagnostics and
treatment of breast cancer, justified by the fact that certain
subtypes of breast cancer do not respond to existing endocrine
therapy. In this respect identification of novel biomarkers and their
implication in diagnostics and targeted therapy remains a high
priority. TP53 is mutated in 80% of basal-like breast tumors.
Strong association between TP53 mutation status and aggressive-
ness of breast cancer is identified [1], and the mutant p53 (mtp53)
up-regulates cholesterol biosynthesis and gives cells a more
metastatic phenotype [2]. In normal cells, wild-type p53 is present
at low levels due to fast turn over, and its stabilization is triggered
by DNA damage followed by activation of signaling cascades that
result in either DNA repair or apoptosis. The oncogenic mtp53
protein lacks this feature, is always stable, and facilitates genomic
instability [3,4]. Cancer cells express mtp53 proteins with a range
of gain-of-function (GOF) activities, contributing to tumor growth
and metastasis [5–8]. In agreement with this hypothesis, mice with
mutant p53 developed a broad spectrum of tumors as compared to
p53 knockout mice [9,10]. Thus discovery of a novel approach
that provides an assessment of metastatic potential of cancer cells
in connection with the p53 activity, will be useful for not only
establishing a more accurate cancer prognosis but also under-
standing the fundamental mechanism of mtp53 oncogenic action.
Recently, differences in mechanical and electrical properties
between cancer cells and normal cells were identified by various
analytical methods [11,12]. One of the most robust approaches to
screen them is to apply hyposmotic pressure and monitor the
degree of cell deformation with impedance change on interdigi-
tated electrodes (i.e., higher deformation leads to higher imped-
ance signal). Cancer cells swell larger and faster due to their softer
and elastic nature. Recently, ovarian and kidney cancer cell lines
could be assayed with the increase of impedance signal on
interdigitated electrodes even when cancer cells were spiked with
the overwhelming number of normal cells in the samples [12].
In the present study we assessed the contribution of mtp53 in
breast cancer cells to the mechanical property of breast cancer
cells. We systematically depleted oncogenic mtp53 in breast cancer
cells, hypothesizing that metastasized cells are more elastic and
deform their cellular shape more dynamically than those cells
whose mtp53 has been knocked down. The swelling event under
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hyposmotic pressure induced by adding water was indeed
observed in aggressive mtp53-displaying breast cancer cells by
fluorescence microscopy, and larger scale measurements of
swelling cancer cells were accomplished by the impedance
detection. The degree of elasticity of breast cancer cells can be
correlated with the expression of mtp53, supporting the hypothesis
that more metastatic cancer cells driven by mtp53 are softer and
more deformable in hyposmotic pressure. All results in this report
suggest that the mtp53 plays a pivotal role in increasing the
flexibility of breast cancer cells and thus mtp53 expression coupled
with impedance detection may serve as a meaningful fingerprint
for the cancer diagnostics. These results will also have an
important clinical implication for the development of mtp53-
based targeting of detection and treatment.
Materials and Methods
Cell Culture
Cell lines (MDA-MB-231, MDA-MB-468, HCC70 and
HCC1806) were purchased from American Type Culture
Collection (ATCC) and grown in DMEM media, supplemented
with 10% Fetal Bovine Serum and 1% penicillin-streptomycin, at
37uC humidified incubator at 5% CO2.
Generation of Inducible mtp53 Knockdown Cell Lines
Constructs with shRNA for mtp53 or without the shRNA were
generated and introduced into the MDA-MB-231 and MDA-MB-
468 cells by retrovirus mediated gene transfer methods, as
described elsewhere [2]. Briefly, STGM vector with miR30 based
shRNA sequence and complimentary sequence to 2120–2139 of
p53 (STGM-shp53) and rtTA plasmid were transfected into
Phoenix packaging cells to generate retrovirus for infection of the
target cells. The generated viruses were harvested and cells were
co-infected with virus containing rtTA plasmid and the vectors.
After selection with puromycin (STGM vector) and Hygromycin
(rtTA), clonal cell lines were generated by limited dilution method.
Doxocycline was added to induce the expression of the miR30-
based shRNA, which could bind to the complementary fragment
to p53 mRNA and initiate Dicer-mediated degradation of p53
mRNA. The resulting cell lines were named MDA-231.shp53 and
MDA-468.shp53 respectively. Three clones are described in this
work (MDA-231.shp53 1D10 and 2C9, and MDA-468.shp53
2F3). Two cell lines, MDA-MB-231 and MDA-MB-468, with
empty vectors without p53-complementary oligonucleotide
(STGM) but still containing miR30 based shRNA sequence were
also generated. These two cell lines (MDA-MB-231 vector STGM
and MDA-MB-468 vector STGM) and the parental MDA-MB-
231 were used as negative controls. Cells were incubated with
8 mg/ml doxycycline (dox) for 6 days to knockdown mtp53.
Western Blotting
Cells were lysed in RIPA buffer (0.1% SDS, 1% NP-40, 0.5%
Deoxycholate, 150 mM NaCl, 1 mM EDTA, 0.5 mM EGTA,
50 mM Tris pH 8) containing 1 mM PMSF, 8.5 mg/ml Aprotinin
and 2 mg/ml Leupeptin. SDS-PAGE was used to separate 50 mg
of total protein cell extract per lane. Following electro-transfer to
nitrocellulose membrane, immunoblotting was done with an anti-
p53 antibody. Actin and lamin were used as loading controls.
Monitoring Cell Swelling Using Inverted Epifluorescence
Microscopy
Cells were seeded in complete medium on BD poly-D-lysine
multiwell plates and cultured for 1 h. Wheat germ agglutinin
conjugate (0.5 mg/mL, Invitrogen) was added for 20 min to label
Figure 1. Schematic illustration of the response of various breast cancer cell lines to doxycycline treatment. The degree of the
expression of mtp53 in shp53 cell lines (Figures 1 A–C) can be controlled with the treatment of dox, while the mtp53 expression in parental and
vector-STGM cell lines remains unchanged.
doi:10.1371/journal.pone.0099351.g001
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plasma membrane of the cells. Subsequently, the medium was
replaced by deionized water to induce the hyposmotic stress. Cells
remained attached to the plate surface during the swelling
experiment. The increase and the variability of the diameter were
determined by a series of Fluorescence micrographs taken by a
Nikon Eclips TE200 inverted epifluorescence microscope. The
mean increase in volume during swelling was analyzed using
ImageJ software for 40 cells before and after undergoing the
hyposmotic stress.
Impedimetric Measurements for the Detection of Cell
Deformation
The single-shell theory suggests that since cells are surrounded
by dielectric shells in low permittivity with conductive electrolyte
cores they can be treated as insulated spheres [13]. When an
alternating current (AC) field with the frequency less than 1 MHz
is applied on electrodes, the deposition of such insulated cells alters
the distribution of electric-field lines on interdigitated electrodes,
leading to the impedance change around the electrodes [14].
When the volume of insulating objects becomes larger on
electrodes, the deviation of the electric-field lines increases and
then this structural change sensitively influence the electric
environment around the electrode [15], leading to the enhance-
ment of impedance signal. To measure cell deformability using
interdigitated electrodes, 218 polysilicon fingers (1600 mm-long,
3 mm-wide and a 3 mm-spacing with each other) were fabrication
as described elsewhere [15]. The electrodes were incubated with
polylysine (0.1 mg/mL, poly-D-lysine hydrobromide) for 30 min,
rinsed with deionized water and dried under nitrogen gas to
ensure adhesion of cells on the transducer surface. Cancer cells
were seeded on top of electrode in a 5 ml volume and incubated for
30 min in a humidified chamber. Following the incubation, the
electrode was rinsed three times with deionized water and real-
time impedimetric measurements by the polysilicon transducer
were recorded at 20 kHz, 10 mV.
For the analysis of deformability using a commercial impedance
analyzer, xCELLigence, a 16-well plate (e-plate 16, ACEA
Biosciences, Inc.) was incubated with 100 ml of poly-L-Lysine for
30 min, rinsed with deionized water and dried in a cell culture
hood under UV light. On a poly-L-Lysine coated plate in
quadruplicate, 2000 cells were plated per well. Following 2 hours
of cell stabilization on plates at 37uC, culture media was replaced
with dH2O and the impedance measurement was recorded every
2 seconds for 10 minutes. Impedance values were automatically
converted to Cell Index (CI), relative impedance change at every
measurement point. The xCELLigence system measures imped-
ance at three discrete frequencies, 10 kHz, 25 kHz, and 50 kHz
and it plots averaged impedance CI values among these
frequencies.
Results and Discussion
The aim of our work is to probe changes in the mechanoelastic
property of breast cancer cells associated with the expression of
mtp53. We hypothesized that high expression of mtp53 in two
types of breast cancer cells (MDA-MB-468 (with mtp53 R280H)
and MDA-MB-231 (with mtp53 R273L)) leads to softening of cell
structure and the hyposmotic pressure induces swelling of these
cells in contrast with ones devoid of mtp53. Thus we expected that
the removal of mtp53 would decrease elasticity and revert cells to a
stiffer normal phenotype. To test this hypothesis, we induced
depletion of mtp53 in shRNA-mediated knockdown cell lines,
MDA-231.shp53 (Figure 1-A, B) and MDA-468.shp53 (Figure 1-
C), and analyzed their mechanoelastic change before and after the
knockdown. The shRNA cancer cells were generated through
miR30-based knockdown of mtp53 induced by doxycycline. While
doxycycline controls the degree of the expression of mtp53 in
shp53 cell lines (Figures 1-A–C) it does not influence the mtp53
expression in parental and vector-STGM cell lines (Figures 1-D–
F); The engineered MDA-MB-231 vector STGM cells and MDA-
MB-468 vector STGM cells express the same proteins as MDA-
MB-231 and MDA-MB-468 except without mtp53.shRNA and
Figure 2. Western blot analysis of the expression of mtp53 in cells with or without the treatment of dox. A. MDA-231.shp53 (clone
1D10), B. MDA-231.shp53 (clone 2C9), C. MDA-468.shp53 (clone 1F5), D. MDA-MB-231 parental, E. MDA-MB-231 STGM, and F. MDA-MB-468 STGM
breast cancer cells. Actin is control for A, C, D, F and lamin is control for B and E.
doi:10.1371/journal.pone.0099351.g002
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thus doxycycline cannot knockdown mtp53. Therefore, the
parental MDA-MB-231, MDA-MB-468 vector STGM and
MDA-MB-231 vector STGM cells served as negative controls.
And the cellular mechanical property should also reflect this
metastatic behavior change based on our hypothesis.
First, the expression of mtp53 in each cell line with or without
the treatment of doxycycline was examined by western blot
analysis. In the MDA-231.shp53 and the MDA-468.shp53
(Figures 2-A, B, and C), harboring the shRNA designed to
knockdown mtp53, the levels of mtp53 protein was decreased after
the addition of doxycycline. Figures 2-D, E, and F show the
expression of mtp53 in MDA-MB-231 parental, MDA-MB-231
STGM and MDA-MB-468 STGM cells remained at the same
level before and after the doxycycline addition. Then, we analyzed
change in volume of each individual cell via application of
hyposmotic pressure with or without the treatment of doxycycline
by fluorescence microscopy. After plasma membranes of these cells
were stained by a fluorescent dye, wheat germ agglutinin
conjugate, and immersed in deionized water for the hyposomosis,
fluorescence micrographs showed that MDA-231.shp53 and
MDA-468.shp53 cells increase diameters significantly by
3565%, 3764% and 3866%, respectively, after adding deionized
water for 120s (Figures 3-A, B and C). When these cells were
treated with doxycycline for the reduction of mtp53, the diameter
change of MDA-231.shp53 and MDA-MB-468.shp53 cells was
significantly reduced as compared to the non-doxycycline-treated
cancer cells to 2264%, 2164%, 1363%, respectively. These
trends suggest that higher expression of mtp53 on the breast
cancer cell lines has correlation with larger volume changes as the
hyposmotic pressure was applied. As a control, we confirmed that
there is no difference in the swelling ratio of MDA-MB-231
parental in the presence of doxycycline after adding water
(3766% with no doxycycline, 3767% with doxycycline,
Figure 3-D), consistent with the hypothesis that the cause of
elastic nature is due to the expression of mtp53 rather than the
doxycycline treatment. Both MDA-MB-231 STGM and MDA-
MB-468 STGM cells swell in the same expansion percentage
before and after adding doxycycline (Figures 3-E and F), further
supporting that the reduced elasticity of shp53 cell lines is
specifically caused by mtp53 knockdown, not by the presence of
mir-30 sequence and STGM vector. Recently, the higher degree
of metastasis can be correlated with the higher mtp53 expression
Figure 3. Fluorescence micrographs of stained plasma membranes of various cells. Cells were examined in the culture medium and then
in deionized water at 120 s. A. MDA-231.shp53 (clone 1D10), B. MDA-231.shp53 (clone 2C9), C. MDA-468.shp53 (clone 2F3), D. MDA-MB-231 parental,
E. MDA-MB-231 STGM, and F. MDA-MB-468 STGM breast cancer cells. Scale bar = 60 mm.
doi:10.1371/journal.pone.0099351.g003
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in breast cancer cells [8], and thus cancer cells that have higher
metastatic potential due to expression of mtp53 could have altered
mechanoelastic properties and be more aggressive due to
increased elasticity.
To confirm this trend of structural transformation with a larger
number of cells, we investigated the impedance variation of
mtp53-containing breast cancer cells on the order of 1,000 cells
before and after applying hyposmotic pressure. Previously, ovarian
and kidney cancer cell lines were confirmed to increase impedance
values as these cells were swelled by mixing with water [12] and
here we used the same protocol to correlate the elastic structural
characteristic with the degree of mtp53 expression and the
metastatic feature. After interdigitated electrodes were coated with
polylysine for cell adhesion, 5 mL of cell suspension was incubated
on top of the electrode and then deionized water was added to
trigger the swelling via the increase of hyposmotic stress.
Figure 4. Variations of impedance (Z’) as the function of time resulted from the swelling under hyposmotic stress. With regard to all
the samples, 1000 cancer cells with dox (solid lines) or without dox (dotted lines) were incubated with electrodes for 30 min. A. MDA-231.shp53
(clone 1D10), B. MDA-231.shp53 (clone 2C9), C. MDA-468.shp53 (clone 2F3), D. MDA-MB-231 parental, E. MDA-MB-231 STGM, and F. MDA-MB-468
STGM breast cancer cells.
doi:10.1371/journal.pone.0099351.g004
Figure 5. Average variations of the impedance (CI) as the function of time resulted from the swelling. MDA-468.shp53 cell line (black)
and the one treated with doxycycline (gray) were measured under hyposmotic stress in three sets of 16-well plates simultaneously using xCelligence
system.
doi:10.1371/journal.pone.0099351.g005
Impedimetric Detection of Metastatic Breast Cancer Cells
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Impedance changes in MDA-231.shp53 and MDA-468.shp53
cells were measured over time at 20 kHz, the same protocol
previously optimized for the sensitive detection of cancer cells [12].
The real part of the impedance (Z’) increased rapidly for all of
these cells, indicating that these cells are elastic. However, after
addition of doxycycline their impedance values decreased and the
difference became clear after 60 s of swelling time due to the
reduced elasticity (Figures 4 -A, B, and C). All control cell lines,
MDA-MB-231 parental, MDA-MB-231 STGM and MDA-MB-
468 STGM, also showed the same impedance values through the
swelling time with and without doxycycline (Figures 4-D, E, and
F), meaning that these cells swelled in the same volume expansion
% regardless of the presence of doxycycline. The detection limit of
breast cancer cells with and without mtp53 expression is 2 cells/
mL with two times the standard deviation of blank signal in the
swelling time of 120 s. Thus, this comparison suggests that breast
cancer cells with different levels of mtp53 could be screened by the
impedance variation induced by the volume change under the
hyposmotic pressure in the range of swelling time between 60 s
and 120 s where the impedance difference between mutant breast
cancer cells and the one with mtp53 knockdown is significant. It
should be noted that the size of MDA-231.shp53 increased with
the incubation time and reached the plateau at 60 s of the
incubation time (Figure S1), agreeing with the impedance change
profile in Figure 4. From this observation, the cell expansion limit
in an average size change % was determined as 38%. The
agreement between the size change and the impedance profiles
indicates that there is no major loss of cancer cells via lysis in the
range of impedance measurement times; because no significant
size change is observed after 60 s of incubation time under
hyposmotic pressure, the impedance values of cells should be
decreased if many cells are lost by lysis. However, the decrease of
impedance values is not observed as shown in Figure 4, supporting
that lysis does not interfere with the impedance measurement. In
addition, a major loss of cells is not recognized in a series of
fluorescence images under osmosis. The feature for no size change
of cells after a few minutes of the osmosis is consistent with cells
returning to iso-osmotic medium, which was also previously
observed in other cells and mutants [16].
In order to further confirm the trend we observed between the
expression of mtp53 and the elasticity of breast cancer cell lines
with larger sample sets, impedance changes of these cells were
analyzed by a commercially available impedance analyzer,
xCELLigence impedance analysis system (ACEA Biosciences,
Inc.), containing three sets of 16-well plates for simultaneous
measurements. With the same protocol using a short cell
attachment phase followed by the addition of water, Cell Index
(CI) of swelling was measured every 2 seconds over a period of
10 minutes. The electric swelling assay, using xCELLigence
system was performed in a CO2 incubator, the standard detection
compartment of xCELLigence reducing the impedance fluctua-
tion. Consistently with our initial results a significant increase of
the impedance change was detected in MDA-468.shp53 cells
expressing mtp53 as compared to the cells where mtp53 was
knocked down (Figure 5). This result confirms that mtp53
knockdown in the MDA-468.shp53 cell line partially restored
cellular rigidity with higher statistical confidence.
To further correlate the origin of impedance signal enhance-
ment with mtp53 expression, we performed impedance studies on
two additional breast cancer cell lines, the breast cancer cell line
HCC70 expressing mtp53 and the breast cancer cell line
HCC1806 that does not express any p53 protein. We found that
HCC70 cells generated a substantially higher impedance signal
during cell swelling as compared to HCC1806 cells without p53
expression using both detection methods (Figure 6). Because the
expression of mtp53 is independent of the effect of the shRNA and
STGM vector for these cells, this result supports that the degree of
mtp53 expression is related to the impedance signal in breast
cancer cells and this correlation is valid with and without the
triggering process of shRNA expression.
In summary, these studies provide new insights into under-
standing the role of mtp53 in the increased elasticity of cell
structure in cancer cells. The cell swelling ratio under hyposmotic
pressure is proportional to the impedance signal enhancement on
interdigitated electrodes. This approach could be applied to
characterize when breast cancer cells with high mtp53 expression
(MDA-231.shp53 and MDA-468.shp53) and to observe reversion
to more normal and stiffer isotypes as mtp53 is knocked down by
Figure 6. Average variations of the impedance (CI) as the function of time resulted from the swelling.Mtp53-expressing cell lines (MDA-
231.shp53 (clone 1D10) (dotted black), HCC70 (solid black)) and no p53-expressing cell line (HCC1806, solid grey) were measured under hyposmotic
stress using xCELLigence system.
doi:10.1371/journal.pone.0099351.g006
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shRNA. Moreover, our work revealed that other breast cancer cell
lines HCC70 and HCC1806, which originally have different
expression levels of mtp53, could be distinguished by their
impedance signal. This outcome demonstrates that the expression
of mtp53 positively correlates with the deformability of cancer
cells, which can potentially be applied as an inherent cell marker
for metastatic competence [17]. The described impedance-based
sensor can be used to test effect of mtp53-targeted drugs with
respect to the change in ability of cancer cells to exhibit
tumorigenic deformability.
Supporting Information
Figure S1 Percent variation of the diameter of MDA-
231.shp53 (clone 1D10) breast cancer cells in deionized
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